

## HF Orome



### Business area

*Diagnostics*

### Market sector

*Cardiology, Cardiovascular  
diseases*

### Medical Indication

*Heart failure*

## Research goal

HF\_OROME kit is a method to identify patients at high risk of re-entry or death after hospitalization for "de novo" heart failure. It consists of the detection of two proteins (Orosomuroid and Omentin) in plasma by means of a modified ELISA.

## Problem to solve

Cardiovascular diseases are due to disorders of the heart and blood vessels and are the leading cause of death worldwide, in fact, in 2015, 32% of all deaths (that is, 18 million people) were due to this type of condition. Each year, cardiovascular diseases (CVD) cause 3.9 million deaths in Europe, accounting for 45% of all deaths in Europe. In 2015, more than 85 million people in Europe lived with cardiovascular diseases.

In the last 25 years, the absolute number of cases of CVD has increased in Europe, however, the prevalence rate by age has declined.

## Innovation

HF Orome has a differential value with respect to the alternatives diagnosis and / or prognosis, where the European guidelines recommend the determination of type B natriuretic peptide (BNP) and N-terminal BNP (NT-proBNP) in plasma. However, its efficiency as a prognosis is low due to its modification by other factors such as age, renal failure or obesity. Therefore, one of its clear advantages lies in being a prognostic marker independent of age or associated risk factors. The HF\_OROME kit represents a great advance with respect to the current tests since it could be used in POC and also identifies the patients with higher risk independently of age, heart rate, renal function and NTproBNP.

## Market opportunity

Global market for cardiac biomarkers is \$ 4.81 billion (Technavio, 2016). It is estimated that it will grow at an annual composite rate close to 18% during the 2016-2024 period, reaching \$ 13.3 billion in the year 2024, according to a report by Grand View Research, 2016.



Global market for cardiac biomarkers

## Research team

Cardiology Research Group of the Health Research Institute of Santiago de Compostela:


- **Sonia Eiras Penas:** Principal Investigator of the project
- **José Ramón González-Juanatey:** Head of the Cardiology Service of the University Hospital of University Clinical Hospital of Santiago de Compostela.
- **Rosa M.ª Agra Bermejo.**

## Intellectual property

Patent Request.

**EP17382100.0** Method for prognosis of the outcome of patients with heart failure (HF)

## Development stage:



Available for: *Licensing, co-development*